右美托咪定联合地佐辛对腹腔镜卵巢癌根治术患者肿瘤因子、免疫功能水平及相关血清因子的影响  

Effects of dexmedetomidine combined with dezocine on tumor factors,immune function levels and related serum factors in patients with laparoscopic surgery for ovarian cancer

作　　者：李雪丹[1] 黄杰[1] 黄柯冰 LI Xue-dan;HUANG Jie;HUANG Ke-bing(Department of Operative Anesthesiology,Hanzhong Central Hospital,Hanzhong,723000,Shaanxi Province,China)

机构地区：[1]汉中市中心医院手术麻醉科

出　　处：《海南医学院学报》2019年第11期867-870,876,共5页Journal of Hainan Medical University

基　　金：陕西省自然科学基金项目(中青年人才项目)(2016JQ2341)~~

摘　　要：目的:探讨右美托咪定联合地佐辛对腹腔镜卵巢癌根治术患者肿瘤因子、免疫功能水平及相关血清因子的影响。方法:将我院诊治并拟行腹腔镜卵巢癌根治术的120例患者作为观察对象随机分为对照组和实验组。对照组麻醉采用地佐辛,实验组麻醉采用右美托咪定联合地佐辛。检测并比较两组手术前后血清人附睾蛋白4(HE4)、甲壳质酶蛋白40(YKL-40)、恶性肿瘤特异性生长因子(TSGF)、神经元特异性烯醇化酶(NSE)、S100β蛋白、丙二醛(MDA)、超氧化物歧化酶(SOD)水平及外周血CD3^+、CD4^+、CD8^+并计算CD4^+/CD8^+。结果:手术前,两组血清HE4、YKL-40、TSGF、NSE、S100β蛋白、MDA、SOD水平比较,差异无统计学意义(P>0.05);手术后,两组血清HE4、YKL-40、TSGF、NSE、S100β蛋白、MDA、SOD水平与同组手术前比较,差异具有统计学意义(P<0.05);且手术后实验组各指标改善情况优于对照组,差异具有统计学意义(P<0.05);手术前,两组外周血CD3^+、CD4^+、CD8^+水平及CD4^+/CD8^+之间比较,差异无统计学意义(P>0.05);手术后,两组外周血CD3^+、CD4^+水平及CD4^+/CD8^+与同组手术前比较,差异具有统计学意义(P<0.05);且手术后实验组各项考察指标的水平改善程度优于对照组,差异具有统计学意义(P<0.05)。结论:右美托咪定联合地佐辛能够明显降低腹腔镜卵巢癌根治术患者血清HE4、YKL-40、TSGF、NSE、S100β蛋白等肿瘤细胞因子水平,减轻氧化应激反应,且对细胞免疫功能的影响较小。Objective: To study the effects of dexmedetomidine combined with dezocine on tumor factors, immune function levels and related serum factors in patients with laparoscopic surgery for ovarian cancer. Methods: To select 120 cases of laparoscopic ovarian cancer treated and planned to undergo laparoscopic radical operation in our hospital were randomly and equally divided into control group and treatment group. The patients in control group were treated with dezocine, the treatment group were treated with dexmedetomidine combined with dezocine. To detect and compare the serum HE4, YKL-40, TSGF, NSE, S100β protein, MDA, SOD and peripheral blood CD3^+, CD4^+, CD8^+ and calculate CD4^+/CD8^+ before and after operation. Results: Before the surgery, there was no significant difference in serum HE4, YKL-40, TSGF, NSE, S100β protein, MDA and SOD between the two groups( P >0.05). After surgery, there were significant differences between the two groups in serum HE4, YKL-40, TSGF, NSE, S100β protein, MDA and SOD levels and the same group before surgery( P <0.05), the improvement of each index in the treatment group was better than those in the control group, and the differences were significantly( P <0.05). Before the surgery, the differences between the two groups in peripheral blood CD3^+, CD4^+, CD8^+ and CD4^+/CD8^+ had no significant difference ( P >0.05), After surgery, the differences between the two groups and the same group before operation in peripheral blood CD3^+, CD4^+, CD8^+ levels and CD4^+/CD8^+ were significantly( P <0.05), the improvement of each index in the treatment group was better than that in the control group, the differences were significantly ( P <0.05). Conclusion: Dexmedetomidine combined with dezocine can reduce the serum HE4, YKL-40, TSGF, NSE, S100β protein levels in patients with ovarian cancer after laparoscopic operation, reduce the oxidative stress reaction, has smaller effect on cellular immune function.

关 键 词：右美托咪定 地佐辛 腹腔镜卵巢癌根治术 肿瘤因子 免疫功能 氧化应激 

分 类 号：R614[医药卫生—麻醉学] R737.31[医药卫生—外科学]